Avalyn Completes Oversubscribed $100 Million Series D Financing to Further Advance Clinical Development of Novel Inhaled Therapies for Pulmonary Fibrosis
Financing led by Suvretta Capital Management and SR One with participation from 16 additional healthcare investors
Proceeds will support key clinical milestones across all of Avalyn's pipeline programs
CAMBRIDGE, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., a clinical-stage biopharmaceutical company focused on the development of inhaled therapies for the treatment of life-threatening pulmonary diseases, today announced the closing of an oversubscribed $100 million Series D financing. The raise was co-led by Suvretta Capital Management and SR One, with participation from Novo Holdings A/S, F-Prime, Perceptive Xontogeny Venture Funds, Norwest, Eventide Asset Management, Wellington Management, Vida Ventures, Catalio Capital Management, RiverVest Venture Partners, Pivotal bioVenture Partners, TPG Biotech, Hamilton Square Partners Management, LP (HSq), Rock Springs Capital, Surveyor Capital (a Citadel company), funds and accounts advised by T. Rowe Price Associates, Inc., and Piper Heartland. In conjunction with the financing, David Friedman, M.D., Managing Director of Suvretta Capital Management, joined Avalyn's Board of Directors and Diamantis Xylas, M.D., Partner and Head of Research of Catalio Capital Management, joined as a Board Observer.
"Completing a significant round of financing despite the challenging market conditions is a testament to our innovative approach to developing potentially life-saving medicines for patients with pulmonary fibrosis," said Lyn Baranowski, CEO of Avalyn. "We've made tremendous progress across our entire portfolio, completing Phase 1 clinical trials of AP02 and initiating a global Phase 2b clinical trial of AP01. With the support from an esteemed group of investors, we will continue the expeditious advancement of our clinical programs, while also bringing our third program into the clinic, all of which positions Avalyn for an exciting future of growth."
Proceeds will support key clinical milestones across Avalyn's pipeline programs in pulmonary fibrosis, including ...
